ÂÜÀòÂÒÂ×

David Karp is a seasoned finance executive with extensive experience in leadership roles across various companies in the biotechnology and technology sectors. Currently serving as Chief Financial Officer at Gandeeva Therapeutics since September 2021, David Karp drives the finance function to support the company's rapid growth and innovation. Previous experience includes advising the CEO at Alianza, Inc., and a long tenure at CounterPath, where David held multiple leadership positions, including Chief Executive Officer and Chief Financial Officer, significantly improving revenue and transitioning the business model to recurring revenue. Earlier roles include Chief Financial Officer positions at Chemokine Therapeutics and Neuro Discovery Inc., where David successfully led IPOs and capital funding initiatives. David Karp began their career as a Financial Analyst at Repap Enterprises Inc. and has a solid educational background, holding an MBA in Finance from Ivey Business School and a BASc in Mechanical Engineering from the University of Waterloo.